Close

CTI BioPharma (CTIC) Announces Pacritinib Phase 3 Met One co-Primary Endpoint; TSS Reduction Endpoint Missed

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/24/2024

1. TSLA
2. ENPH
3. TXN
4. BA
5. SPOT
6. META
7. V
8. IBM
9. KMB
10. HCP


Go back to CTI BioPharma (CTIC) Announces Pacritinib Phase 3 Met One co-Primary Endpoint; TSS Reduction Endpoint Missed

CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis

August 29, 2016 6:00 AM EDT

SEATTLE, Aug. 29, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with physician-specified best available therapy (BAT), including ruxolitinib, for... More